Edoxaban eliminates hypercoagulability evoked by transient temperature changes in human whole blood

Area of Science:

• Cardiovascular Medicine
• Hematology
• Biomedical Engineering

Background:

• Thrombosis is a critical complication of radiofrequency and cryoablation procedures.
• Temperature extremes during ablation may alter blood coagulability.
• Investigating the impact of thermal stimulation on blood coagulation is crucial.

Purpose of the Study:

• To determine the effect of transient temperature changes on whole blood coagulability.
• To assess whether edoxaban can suppress temperature-induced hypercoagulability.
• To understand the mechanisms underlying ablation-related thrombosis.

Main Methods:

• Whole blood samples from healthy subjects were subjected to heat (50°C) and cryostimulation (-20°C).
• Tissue factor and varying concentrations of edoxaban were added to blood samples.
• Blood coagulability was measured using dielectric coagulometry, assessing the end of acceleration time (EAT).

Main Results:

• Both heat and cryostimulation significantly shortened EAT, indicating induced hypercoagulability.
• Tissue factor potentiated and prolonged the hypercoagulable state.
• Edoxaban demonstrated a concentration-dependent increase in EAT, suppressing temperature-induced hypercoagulability.

Conclusions:

• Transient thermal stimulations, both heat and cold, induce hypercoagulability in whole blood.
• Edoxaban at concentrations of 100 ng/mL and above effectively mitigates temperature-stimulated hypercoagulability.
• These findings suggest a potential therapeutic role for edoxaban in preventing ablation-related thrombosis.